Cohance Lifesciences Ltd vs Hester Biosciences Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 18, 2026

Key Highlights

The Latest Trading Price of Cohance Lifesciences Ltd is ₹ 429.5 as of 18 May 15:30 . The P/E Ratio of Cohance Lifesciences Ltd changed from 34.8 on March 2021 to 110.3 on March 2025 . This represents a CAGR of 25.95% over 5 yearsThe P/E Ratio of Hester Biosciences Ltd changed from 47.4 on March 2021 to 38.8 on March 2025 . This represents a CAGR of -3.92% over 5 years The Market Cap of Cohance Lifesciences Ltd changed from ₹ 12611 crore on March 2021 to ₹ 29524 crore on March 2025 . This represents a CAGR of 18.55% over 5 yearsThe Market Cap of Hester Biosciences Ltd changed from ₹ 1630 crore on March 2021 to ₹ 1066 crore on March 2025 . This represents a CAGR of -8.14% over 5 years The revenue of Cohance Lifesciences Ltd for the Mar '26 is ₹ 617.28 crore as compare to the Dec '25 revenue of ₹ 550.71 crore. This represent the growth of 12.09% The revenue of Hester Biosciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 79.4 crore. This represent the decline of -100% The ebitda of Cohance Lifesciences Ltd for the Mar '26 is ₹ 80.33 crore as compare to the Dec '25 ebitda of ₹ 96.65 crore. This represent the decline of -16.89% The ebitda of Hester Biosciences Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 19.78 crore. This represent the decline of -100% The net profit of Cohance Lifesciences Ltd changed from ₹ 75.37 crore to ₹ 8.31 crore over 8 quarters. This represents a CAGR of -66.80% The net profit of Hester Biosciences Ltd changed from ₹ 7.49 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of -100.00% The Dividend Payout of Cohance Lifesciences Ltd changed from 16.5 % on March 2021 to 0 % on March 2025 . This represents a CAGR of -100.00% over 5 yearsThe Dividend Payout of Hester Biosciences Ltd changed from 21.33 % on March 2021 to 18.71 % on March 2025 . This represents a CAGR of -2.59% over 5 years .

About Cohance Lifesciences Ltd

Cohance Lifesciences Limited, formerly known as Suven Pharmaceuticals Limited was incorporated on November 6, 2018.
The name of the Company has been changed to Cohance Lifesciences Limited w.e.f.
May 7, 2025.
Cohance Lifesciences Ltd is an integrated Contract Development and Manufacturing Operations (CDMO) company that serves leading global life science and fine chemical majors.
The Company's comprehensive services encompass- Custom Synthesis, Process R&D, Scale-Up, and Contract Manufacturing of intermediates, APIs, and formulations. Company is engaged in the business of development and manufacturing of New Chemical Entity (NCE) based Intermediates, Active Pharmaceutical Ingredients (API), Speciality Chemicals and formulated drugs under contract research and manufacturing services for global pharmaceutical, biotechnology and chemical companies.

About Hester Biosciences Ltd

Hester Biosciences Limited is one of the leading and pioneering animal healthcare companies in India.
The Company was incorporated in April, 1987 and is engaged in manufacturing of Poultry vaccines and Large Animal Vaccines and trading of Poultry and Large animal and Petcare health products having its manufacturing set up at Meda Adraj Village, Mehsana District, Gujarat. The Company built a presence in several regions of Africa and in numerous nations, including Vietnam, Indonesia, Nepal, and Bangladesh.
The products and services included over 51 vaccines and 70+ health products.
In addition, it offers a vast selection of pharmaceuticals, feed supplements, and disinfectants for poultry and large animals. The Company markets and distributes veterinary and pharmaceutical products like animal health products, poultry vaccines, poultry diagnostic, laboratory kits and reagents.

FAQs for the comparison of Cohance Lifesciences Ltd and Hester Biosciences Ltd

Which company has a larger market capitalization, Cohance Lifesciences Ltd or Hester Biosciences Ltd?

Market cap of Cohance Lifesciences Ltd is 16,431 Cr while Market cap of Hester Biosciences Ltd is 1,505 Cr

What are the key factors driving the stock performance of Cohance Lifesciences Ltd and Hester Biosciences Ltd?

The stock performance of Cohance Lifesciences Ltd and Hester Biosciences Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Cohance Lifesciences Ltd and Hester Biosciences Ltd?

As of May 18, 2026, the Cohance Lifesciences Ltd stock price is INR ₹429.5. On the other hand, Hester Biosciences Ltd stock price is INR ₹1770.3.

How do dividend payouts of Cohance Lifesciences Ltd and Hester Biosciences Ltd compare?

To compare the dividend payouts of Cohance Lifesciences Ltd and Hester Biosciences Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.